Synergy between publication and promotion: comparing adoption of new evidence in Canada and the United States
- 15 October 2003
- journal article
- research article
- Published by Elsevier in The American Journal of Medicine
- Vol. 115 (6) , 467-472
- https://doi.org/10.1016/s0002-9343(03)00422-4
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Revisiting the Canadian Health Care SystemNew England Journal of Medicine, 2000
- ACE Inhibition in Cardiovascular DiseaseNew England Journal of Medicine, 2000
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Aldosterone and Spironolactone in Heart FailureNew England Journal of Medicine, 1999
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Influence of a Randomized Clinical Trial on Practice by Participating Investigators: Lessons From the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT)Journal of the American College of Cardiology, 1998
- Therapeutic-Class Wars -- Drug Promotion in a Competitive MarketplaceNew England Journal of Medicine, 1994
- Use of Medical Resources and Quality of Life after Acute Myocardial Infarction in Canada and the United StatesNew England Journal of Medicine, 1994
- Do the Results of Randomized Clinical Trials of Cardiovascular Drugs Influence Medical Practice?New England Journal of Medicine, 1992
- Improving Drug-Therapy Decisions through Educational OutreachNew England Journal of Medicine, 1983